Announcements Trials
Browse Landscape

Phase

Phase 2 40Phase 1 20Phase 3 18Phase 1/2 7Phase 4 3Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Dermatologic 1

Conditions

Uveal Melanoma 1Melanoma 1Granuloma, Plasma Cell 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × Crizotinib × Clear all
NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

IDEAYA Biosciences

Phase 2/3 Active not recruiting
420 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT03874273 2019-03-14

Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Unknown
25 enrolled
Plasma cell

Granuloma, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡